AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025

Kalaris Therapeutics, Inc.

Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.
Effective 4:05 pm ET Jan 15; trading on split-adjusted basis Jan 16 under ALVR.
No fractional shares; cash in lieu based on Jan 15 closing price.
Reverse split is part of preparations for proposed merger with Kalaris Therapeutics.
New CUSIP number 019818202; par value and authorized shares unchanged.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kalaris Therapeutics, Inc.: Reverse stock split of common stock at 1-for-23 ratio via Certificate of Amendment to Third Amended and Restated Certificate of Incorporation (effective 2025-01-15).

Change: charter amendment
Effective: 2025-01-15

Exact text from the filing

On January 15, 2025, AlloVir, Inc. (“AlloVir”) filed an amendment (the “Certificate of Amendment”) to its Third Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of AlloVir’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

102 governance changes filed in the last 30 days. Browse all governance changes →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-007077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.